# US 2026/0116877 A1 · New Salt Forms of Sabcomeline

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0116877 A1
- Document ID: US20260116877A1
- Status: Published application
- Kind: A1
- Application number: 19/419,305
- Filed: 2025-12-15
- Published: 2026-04-30
- Earliest claimed: 2024-07-09
- Assignees: Syremis Therapeutics, Ltd.
- Applicants: Syremis Therapeutics, Ltd.
- Inventors: Anton Frenkel
- Web page: https://patentgrep.com/patent/US20260116877A1

## CPC

- C07D 453/02: containing not further condensed quinuclidine ring systems
- C07D 471/08: Bridged systems
- C07C 65/11: with carboxyl groups on a condensed ring system containing two rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The invention relates to the pamoate salt of sabcomeline. The pamoate salt of sabcomeline may be a solid, preferably in a crystalline solid. The invention also relates to various polymorphic forms of sabcomeline pamoate salt. The invention further relates to methods of preparing the pamoate salt of sabcomeline and its various polymorphic forms and to pharmaceutical compositions containing the pamoate salt of sabcomeline and its various polymorphic forms.

## Claims

### Claim 1

Crystalline sabcomeline pamoate.

### Claim 2 (depends on 1)

The crystalline sabcomeline pamoate of claim 1, wherein the crystalline sabcomeline pamoate exhibits X-ray powder diffraction (XRPD) pattern 2θ peaks at 7.1±0.2, 17.8±0.2 and 21.7±0.2.

### Claim 3 (depends on 2)

The crystalline sabcomeline pamoate of claim 2, wherein the crystalline sabcomeline pamoate comprises Form II of sabcomeline pamoate.

### Claim 4 (depends on 2)

The crystalline sabcomeline pamoate of claim 2, wherein the crystalline sabcomeline pamoate is Form II sabcomeline pamoate.

### Claim 5 (depends on 4)

The crystalline sabcomeline pamoate of claim 4, wherein the Form II sabcomeline pamoate has an XRPD substantially as depicted in FIG. 9.

### Claim 6 (depends on 1)

A pharmaceutical composition comprising the crystalline sabcomeline pamoate of claim 1 and at least one pharmaceutically acceptable excipient.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, wherein the crystalline sabcomeline is present in the composition as a single polymorphic form.

### Claim 8 (depends on 6)

The pharmaceutical composition of claim 6, wherein the crystalline sabcomeline is present in the composition as a mixture of two or more polymorphic forms.

### Claim 9

A method of making crystalline sabcomeline pamoate, the method comprising crystallizing sabcomeline pamoate from at least a first solvent and collecting crystallized sabcomeline pamoate.

### Claim 10 (depends on 9)

The method of claim 9, wherein the crystalline sabcomeline pamoate exhibits X-ray powder diffraction (XRPD) pattern 2θ peaks at 7.1±0.2, 17.8±0.2 and 21.7±0.2.

### Claim 11 (depends on 10)

The method of claim 10, wherein the crystalline sabcomeline pamoate comprises Form II sabcomeline pamoate.

### Claim 12 (depends on 10)

The method of claim 10, wherein the crystalline sabcomeline pamoate is Form II sabcomeline pamoate.

### Claim 13 (depends on 12)

The method of claim 12, wherein the Form II sabcomeline pamoate has an XRPD substantially as depicted in FIG. 9.
